Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.

Ítems similars

• Treatment of Vancomycin-Resistant Enterococcus faecium with RP 59500 (Quinupristin-Dalfopristin) Administered by Intermittent or Continuous Infusion, Alone or in Combination with Doxycycline, in an In Vitro Pharmacodynamic Infection Model with Simulated Endocardial Vegetations
  per: Aeschlimann, Jeffrey R., et al.
  Publicat: (1998)
• Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.
  per: Kang, S L, et al.
  Publicat: (1995)
• Pharmacodynamic interaction between RP 59500 and gram-positive bacteria infecting fibrin clots.
  per: Turcotte, A, et al.
  Publicat: (1992)
• Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium.
  per: Herrera-Insúa, I, et al.
  Publicat: (1996)
• Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
  per: Houlihan, H H, et al.
  Publicat: (1997)